Amphotericin B formulations exert additive antifungal activity in combination with pulmonary alveolar macrophages and polymorphonuclear leukocytes against Aspergillus fumigatus.
Deoxycholate amphotericin B (DAMB) and amphotericin B lipid complex (ABLC) additively augmented the fungicidal activity of pulmonary alveolar macrophages against the conidia of Aspergillus fumigatus. DAMB, ABLC, and liposomal amphotericin B similarly displayed additive effects with polymorphonuclear leukocytes in damaging the hyphal elements of A. fumigatus.
Roilides
Emmanuel
E
3rd Department of Pediatrics, University of Thessaloniki, Hippokration Hospital, Thessaloniki GR-54642, Greece.
Lyman
Caron A
CA
Filioti
Joanna
J
Akpogheneta
Onome
O
Sein
Tin
T
Lamaignere
Cristina Gil
CG
Petraitiene
Ruta
R
Walsh
Thomas J
TJ
D000666:Amphotericin B / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D000935:Antifungal Agents / Q000494:pharmacology*; D001232:Aspergillus fumigatus / Q000187:drug effects* / Q000276:immunology* / Q000648:ultrastructure; D001992:Bronchoalveolar Lavage Fluid / Q000166:cytology; D015169:Colony Count, Microbial; D005079:Excipients; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D008055:Lipids; D008081:Liposomes; D016676:Macrophages, Alveolar / Q000187:drug effects / Q000382:microbiology*; D009504:Neutrophils / Q000187:drug effects / Q000382:microbiology*; D010587:Phagocytosis; D011817:Rabbits
D000935:Antifungal Agents; D005079:Excipients; D008055:Lipids; D008081:Liposomes; D000666:Amphotericin B